文献速递免疫规划

TRIF偏向与佐剂效力并非必然相关

Dissociation of TRIF bias and adjuvanticity.
PubMed 文献 · Vaccine · 2020-05-07

本研究比较两种合成无毒LPS脂质A类似物佐剂sMPL与E6020激活TLR4介导先天免疫及增强抗体产生的能力。小鼠巨噬细胞中高剂量sMPL激活MyD88通路与E6020相当,但E6020的TRIF通路激活显著更强(TRIF偏向);Eritoran对sMPL的竞争抑制强于E6020。尽管存在这些差异,两种佐剂在两个免疫模型中增强抗体应答的程度相当,且Ig同种型平衡。数据表明TRIF偏向不一定预测更优佐剂效力。

要点

  • E6020较sMPL呈现显著更强的TRIF通路激活,即TRIF偏向。
  • 高剂量sMPL激活MyD88依赖信号与E6020等效。
  • sMPL与E6020增强抗体应答程度相当,Ig同种型平衡。

核心结论

  • TRIF偏向不一定预测更优的佐剂效力。

研究设计与样本

  • 在体外小鼠巨噬细胞中比较sMPL与E6020激活TLR4介导先天免疫信号的能力。
  • 在两个免疫模型中比较sMPL与E6020增强抗体产生及Ig同种型平衡的效果。

主要发现

  • 高剂量sMPL激活MyD88依赖信号与E6020等效。
  • E6020激活TRIF通路显著多于sMPL,呈现TRIF偏向。
  • Eritoran对sMPL的竞争抑制强于对E6020的抑制。
  • sMPL与E6020增强抗体应答程度相当,Ig同种型平衡。

临床怎么用

  • 评估TLR4佐剂时不应仅依据TRIF偏向预测佐剂效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Toll-like receptors (TLRs), a family of "pattern recognition receptors," bind microbial and host-derived molecules, leading to intracellular signaling and proinflammatory gene expression. TLR4 is unique in that ligand-mediated activation requires the co-receptor myeloid differentiation 2 (MD2) to initiate two signaling cascades: the MyD88-dependent pathway is initiated at the cell membrane, and elicits rapid MAP kinase and NF-κB activation, while the TIR-domain containing adaptor inducing interferon-β (TRIF)-dependent pathway is initiated from TLR4-containing endosomes and results in IRF3 activation. Previous studies associated inflammation with the MyD88 pathway and adjuvanticity with the TRIF pathway. Gram-negative lipopolysaccharide (LPS) is a potent TLR4 agonist, and structurally related molecules signal through TLR4 to differing extents. Herein, we compared monophosphoryl lipid A (sMPL) and E6020, two synthetic, non-toxic LPS lipid A analogs used as vaccine adjuvants, for their capacities to activate TLR4-mediated innate immune responses and to enhance antibody production. In mouse macrophages, high dose sMPL activates MyD88-dependent signaling equivalently to E6020, while E6020 exhibits significantly more activation of the TRIF pathway (a "TRIF bias") than sMPL. Eritoran, a TLR4/MD2 antagonist, competitively inhibited sMPL more strongly than E6020. Despite these differences, sMPL and E6020 adjuvants enhanced antibody responses to comparable extents, with balanced immunoglobulin (Ig) isotypes in two immunization models. These data indicate that a TRIF bias is not necessarily predictive of superior adjuvanticity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Richard K, Perkins DJ, Harberts EM, et al. Dissociation of TRIF bias and adjuvanticity. Vaccine. 2020. PMID: 32389496. doi:10.1016/j.vaccine.2020.04.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。